CRISPR/Cas gene editing in the human germline. (November 2022)

• Record Type: Journal Article
• Authors: Bekaert, B.; Boel, A.; Cosemans, G.; De Witte, L.; Menten, B.; Heindryckx, B.
• Is Part Of: Seminars in cell & developmental biology. Volume 131(2022)
• Page Start: 93
• Page End: 107
• Publication Date: 2022-11
• Subjects: Human germline gene editing -- Loss-of-heterozygosity -- Mosaicism -- CRISPR/Cas9 -- Base editing -- Prime editing; Cytology -- Periodicals; Developmental biology -- Periodicals; 571.6
• DOI: 10.1016/j.semcdb.2022.03.012
• Languages: English
• ISSNs: 1084-9521

Abstract

Abstract: The ease and efficacy of CRISPR/Cas9 germline gene editing in animal models paved the way to human germline gene editing (HGGE), by which permanent changes can be introduced into the embryo. Distinct genes can be knocked out to examine their function during embryonic development. Alternatively, specific sequences can be introduced which can be applied to correct disease-causing mutations. To date, it has been shown that the success of HGGE is dependent on various experimental parameters and that various hurdles (i.e. loss-of-heterozygosity and mosaicism) need to be overcome before clinical applications should be considered. Due to the shortage of human germline material and the ethical constraints concerning HGGE, alternative models such as stem cells have been evaluated as well, in terms of their predictive value on the genetic outcome for HGGE approaches. This review will give an overview of the state of the art of HGGE in oocytes and embryos, and its accompanying challenges.